SYN News and Press, Synthetic Biologics Inc. From 11/03/20

Synthetic Biologics to Report 2020 Third Quarter Operational Highlights and Financial Results on November 10, 2020 -- Conference Call Scheduled for Tuesday, November 10, 2020 at 4:30 p.m. ET -- PR Newswire ROCKVILLE, Md., Nov. 3, 2020 ROCKVILLE, Md. , Nov. ...

Synthetic Biologics (SYN) plunges 42% premarket after announcing the results of a planned interim futility analysis of the investigator-sponsored Phase 2b clinical study of SYN-010 being conducted by Cedars-Sinai Medical Center ((CSMC)).It was concluded that although SYN-010 wa...

Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients PR Newswire ROCKVILLE, Md., Oct. 2, 2020 ROCKVILLE, Md. , Oct. 2, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), ...

Synthetic Biologics, Inc. (SYN) Q2 2020 Earnings Conference Call August 6, 2020, 04:30 PM ET Company Participants Vincent Perrone - Director, Corporate Communication Steven Shallcross - CEO, CFO, Treasurer and Secretary, Director Michael Kaleko - SVP of R&D Conference Call...

Synthetic Biologics (NYSEMKT: SYN ) : Q2 GAAP EPS of -$0.18 in-line. More news on: Synthetic Biologics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

ROCKVILLE, Md. , Aug. 6, 2020 /PRNewswire/ -- Synthetic Biologics, Inc.  (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, t...

The FDA has signed off on a Phase 1 clinical trial evaluating ascending doses of Synthetic Biologics' ( SYN +7.4% ) SYN-020 in healthy volunteers. The study should launch in Q1 2021. More news on: Synthetic Biologics, Inc., Healthcare stocks news, Stocks on the move, Read more ... ...

ROCKVILLE, Md. , July 30, 2020 /PRNewswire/ --  Synthetic Biologics, Inc.  (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need,&...

ROCKVILLE, Md. , July 29, 2020 /PRNewswire/ --  Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced ...

ROCKVILLE, Md. , June 30, 2020 /PRNewswire/ --  Synthetic Biologics, Inc.  (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ("GI") diseases in areas of high unmet need...